{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}],"title":"Very good partial response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"}]}],"title":"Partial response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"}]}],"title":"Minimal response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"13"}]}],"title":"Stable disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"title":"Progressive disease (PD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"Abbreviated criteria for response categories: CR includes the disappearance of the original monoclonal protein (M-protein) from blood and urine, and \\<5% plasma cells in the bone marrow, and no increase in size/number of lytic bone lesions, and disappearance of soft tissue plasmacytomas for \\>=4 weeks. VGPR includes serum and urine M-protein detectable by immunofixation but not electrophoresis, and reduction in 24-hr urinary light chain excretion by \\<100 mg, and disappearance of soft tissue plasmacytomas for \\>= 4 weeks, and no increase in size/number of lytic bone lesions. PR includes a \\>=50% reduction in serum M-protein, and reduction in 24-hr urinary light chain excretion by either \\>=90% or to \\<200 mg, and \\>=50% reduction in size of soft tissue plasmacytomas, and no increase in size/number of lytic bone lesions. MR includes a \\>=25% and \\<=49% reduction in serum M-protein. SD does not meet criteria for the other response categories. See outcome #4 for a definition of PD.","groups":[{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 50 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"OG000","title":"Bendamustine 50 mg/m^2 Cohort"},{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 70 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"OG001","title":"Bendamustine 70 mg/m^2 Cohort"},{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 90 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"OG002","title":"Bendamustine 90 mg/m^2 Cohort"}],"paramType":"NUMBER","populationDescription":"Efficacy population","reportingStatus":"POSTED","timeFrame":"up to 7.5 months (eight 28-day cycles)","title":"Participants' Best Tumor Response as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"participants"}